GSA Capital Partners LLP Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

GSA Capital Partners LLP bought a new position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,720 shares of the medical research company's stock, valued at approximately $876,000.

Several other hedge funds have also modified their holdings of AMGN. Keynote Financial Services LLC boosted its position in shares of Amgen by 0.6% during the 2nd quarter. Keynote Financial Services LLC now owns 4,898 shares of the medical research company's stock worth $1,530,000 after purchasing an additional 30 shares in the last quarter. Ascent Group LLC boosted its holdings in Amgen by 0.3% during the second quarter. Ascent Group LLC now owns 10,949 shares of the medical research company's stock worth $3,421,000 after buying an additional 31 shares in the last quarter. Hofer & Associates. Inc grew its position in Amgen by 0.5% during the second quarter. Hofer & Associates. Inc now owns 6,477 shares of the medical research company's stock worth $2,024,000 after buying an additional 32 shares during the period. Cadinha & Co. LLC grew its position in Amgen by 0.6% during the third quarter. Cadinha & Co. LLC now owns 5,209 shares of the medical research company's stock worth $1,678,000 after buying an additional 32 shares during the period. Finally, Lansing Street Advisors increased its holdings in Amgen by 1.3% in the third quarter. Lansing Street Advisors now owns 2,582 shares of the medical research company's stock valued at $832,000 after buying an additional 32 shares in the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

AMGN has been the topic of several recent research reports. TD Cowen boosted their price objective on shares of Amgen from $381.00 to $383.00 and gave the stock a "buy" rating in a research report on Monday, October 21st. Dbs Bank raised shares of Amgen to a "strong-buy" rating in a report on Monday, September 16th. Wolfe Research started coverage on shares of Amgen in a research report on Friday. They issued a "peer perform" rating on the stock. Royal Bank of Canada restated an "outperform" rating and set a $362.00 price objective on shares of Amgen in a research report on Thursday, September 26th. Finally, Barclays increased their target price on Amgen from $300.00 to $315.00 and gave the company an "equal weight" rating in a report on Monday, October 7th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $333.57.

Amgen Price Performance

NASDAQ AMGN traded down $12.32 on Friday, hitting $283.61. 5,325,131 shares of the company were exchanged, compared to its average volume of 2,323,978. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85. The firm has a 50 day moving average of $320.85 and a two-hundred day moving average of $318.36. The company has a market cap of $152.45 billion, a P/E ratio of 36.31, a P/E/G ratio of 2.53 and a beta of 0.60. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.11 by $0.47. The business had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.96 earnings per share. On average, equities analysts predict that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.17%. The ex-dividend date is Monday, November 18th. Amgen's dividend payout ratio (DPR) is currently 115.24%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.